France· FR:67179699
ORSERDU 345 mg, comprimé pelliculé
A elacestrant product containing dichlorhydrate d'élacestrant, registered in France by STEMLINE THERAPEUTICS (PAYS-BAS). The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Elacestrant is registered in 14 of 19 countries.
Countries holding a registration under ATC L02BA04 (elacestrant), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Elacestrant · ATC L02BA04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of elacestrant costs, country by country.
Normalised to the WHO defined daily dose (0.345 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Elacestrant · price per daily dose (0.345 g)
USD · FX 28 Sept 2026
- CH Switzerland$374.12
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DICHLORHYDRATE D'ÉLACESTRANT
- Manufacturer
- STEMLINE THERAPEUTICS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L02BA04
- ATC class
- Elacestrant
- Defined daily dose
- 0.345 g, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip133400930278499plaquettes aluminium de 28 (4 x 7) comprimés
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elacestrant in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesORSERDUStemline Therapeutics, Inc.
- SwitzerlandOrserdu 345 mg, FilmtablettenStemline Therapeutics Switzerland GmbH
- CzechiaORSERDUStemline Therapeutics B.V., Amsterdam
- SpainORSERDU 345 MG COMPRIMIDOS RECUBIERTOS CON PELICULAStemline Therapeutics B.V.
- FinlandORSERDUStemline Therapeutics B.V.
- BelgiumOrserdu 345 mgStemline Therapeutics
- IcelandOrserduStemline Therapeutics B.V.
- NetherlandsORSERDU 345 mg filmomhulde tablettenStemline Therapeutics B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orserdu
- Liechtenstein · Orserdu
- Norway · Orserdu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f682bdbb-ccaa-437d-9e94-78889905d9ca GET /v1/drugs/f682bdbb-ccaa-437d-9e94-78889905d9ca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67179699",
"date_amm": "2023-09-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1757",
"substance": "DICHLORHYDRATE D'ÉLACESTRANT",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about elacestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.